Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr 23;117(5):1245-1247.
doi: 10.1093/cvr/cvab060.

Apolipoprotein B is an insufficient explanation for the risk of coronary disease associated with lipoprotein(a)

Mark Trinder  1   2 , Seyedeh Maryam Zekavat  2   3 , Md Mesbah Uddin  2 , Akhil Pampana  2 , Pradeep Natarajan  2   4   5   6
Affiliations
Observational Study

Apolipoprotein B is an insufficient explanation for the risk of coronary disease associated with lipoprotein(a)

Mark Trinder et al. Cardiovasc Res. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Apolipoprotein B is sufficient to explain the risk of CAD associated with LDL-C but not lipoprotein(a). (A) The epidemiological estimates for the association of a 50 mg/dL increase in measured LDL-C or 120 nmol/L increase in lipoprotein(a) (∼50 mg/dL) with risk incident CAD are shown for UK Biobank participants (n=327 929). Data are displayed as odds ratios with 95% confidence intervals (calculated by logistic regression adjusted for age and sex). (B) Causal estimates for the relationship between a 50 mg/dL increase in genetically associated LDL-C or lipoprotein(a) mass with risk of CAD are shown as odds ratios with 95% confidence intervals (calculated using an inverse weighted variance Mendelian randomization analysis). Causal estimates are also depicted for the relationship between a 120 nmol/L increase in genetically associated lipoprotein(a) molar concentration and risk of CAD. Mendelian randomization results are depicted as univariable analyses and multivariable analyses that included ApoB. ApoB, apolipoprotein B; CAD, coronary artery disease; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a).
See this image and copyright information in PMC

References

    1. Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, Bjornsson E, Norddahl GL, Jonasdottir A, Jonasdottir A, Eggertsson HP, Gretarsdottir S, Thorleifsson G, Indridason OS, Palsson R, Jonasson F, Jonsdottir I, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Danielsen R, Matthiasson SE, Kristmundsdottir S, Halldorsson BV, Hreidarsson AB, Valdimarsson EM, Gudnason T, Benediktsson R, Steinthorsdottir V, Thorsteinsdottir U, Holm H, Stefansson K.. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 2019;74:2982–2994. - PubMed
    1. Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Smith GD, Holmes MV.. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med 2020;17:e1003062. - PMC - PubMed
    1. Zekavat SM, Ruotsalainen S, Handsaker RE, Alver M, Bloom J, Poterba T, Seed C, Ernst J, Chaffin M, Engreitz J, Peloso GM, Manichaikul A, Yang C, Ryan KA, Fu M, Johnson WC, Tsai M, Budoff M, Vasan RS, Cupples LA, Rotter JI, Rich SS, Post W, Mitchell BD, Correa A, Metspalu A, Wilson JG, Salomaa V, Kellis M, Daly MJ, Neale BM, McCarroll S, Surakka I, Esko T, Ganna A, Ripatti S, Kathiresan S, Natarajan P; NHLBI TOPMed Lipids Working Group. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun 2018;9:2606. - PMC - PubMed
    1. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O’Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N, Donnelly P, Marchini J.. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203–209. - PMC - PubMed
    1. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Angelantonio ED, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol 2018;3:619–627. - PMC - PubMed

Publication types

MeSH terms